Ildong 해시 게임 바카라 to unveil late-September topline Phase 1 clinical trial results for its GLP-1 oral obesity drug candidate

[by Ji, Yong Jun] Ildong 해시 게임 바카라 is scheduled to announce top-line results this month from its Phase 1 clinical trial of ID110521156 (development code), an oral obesity drug candidate under development by its affiliate, Yunovia. ID110521156 is a glucagon-like peptide 1 (GLP-1) receptor agonist (RA).

In June, Ildong 해시 게임 바카라 reported interim findings at the American Diabetes Association (ADA) meeting, where ID110521156 achieved a maximum weight reduction of 11.9% in the low-dose cohort. The forthcoming top-line presentation will provide data on the safety and tolerability of ID110521156, as well as weight loss outcomes in the high-dose group.

According to industry sources, on September 3, Ildong 해시 게임 바카라 will host an investor relations (IR) conference for institutional investors and analysts in Yeouido, Seoul, on September 29, during which it will announce the top-line results of the Phase 1 clinical trial for ID110521156. The presentation will be led by Ildong 해시 게임 바카라's President and COO, Lee Chae-joon, together with Yunovia Headquarters Director Park Joon-tae, who will provide a detailed explanation of the clinical findings and outline the follow-up development strategy for ID110521156.

ID110521156, an oral GLP-1 RA, has been under development by Yunovia, an affiliate of Ildong 해시 게임 바카라, since 2019. The candidate entered Phase 1 clinical trials in September 2023, with top-line results anticipated to be disclosed roughly two years thereafter.

Ildong 해시 게임 바카라 and Yunovia attracted considerable attention in June when they presented interim data on obesity efficacy of ID110521156 in the form of a poster presentation at the ADA meeting in Chicago, USA. According to the company, in the dose-dependent cohorts, the 100 mg dose group achieved an average weight reduction of 6.9% and a maximum reduction of 11.9% over a four-week period. Notably, while 0% of the participants in the placebo group achieved a weight loss of 5% or more, 55.6% of those in the 50 mg group and 66.7% in the 100 mg group reached this clinical meaningful threshold.

A distinguishing feature of the study was the low incidence of gastrointestinal adverse effects, even at higher dose levels. Conventionally, oral 해시 게임 바카라 therapeutics are prone to degradation by digestive enzymes, limiting their ability to reach the intestines and resulting in poor absorption rates.

Novo Nordisk's Rybelsus, an oral 해시 게임 바카라 therapy containing Wegovy (semaglutide), likewise exhibits a low bioavailability of approximately 1%. The key challenge in the development of oral obesity treatments lies in achieving higher absorption while simultaneously minimizing dose-related adverse effects.

Interim results indicated that ID110521156 was associated with markedly fewer gastrointestinal adverse effects across the effective dose range. Market expectations were reflected in the company’s valuation, as Ildong Pharmaceutical's share price (based on closing prices) rose by approximately 78%, from KRW 12,840 (approximately USD 9.2) on June 25 to KRW 22,800 on September 2.

Oral 해시 게임 바카라 therapies for obesity are strongly favored over existing subcutaneous (SC) treatments owing to their markedly superior patient compliance and convenience. Consequently, upon regulatory approval, oral 해시 게임 바카라 agents are expected to capture a substantial share of the current injectable obesity drug market.

According to the Korea Biotechnology Industry Organization (KoreaBio), the global 해시 게임 바카라 treatment market is forecasted to expand at a compound annual growth rate (CAGR) of 48.4%, rising from USD 6.68 billion (KRW 9.5 trillion) in 2023 to USD 48 billion by 2028.

In Korea, in addition to Ildong 해시 게임 바카라, several companies like Hanmi 해시 게임 바카라, D&D Pharmatech, and ProGen are pursuing the development of novel oral obesity drugs targeting the GLP-1 class. Among these, Ildong 해시 게임 바카라's ID110521156 represents the most advanced study currently in clinical development.